Three therapies for rare disorder HAE are overpriced, says ICER

Influential cost-effectiveness watchdog ICER - the Institute for Clinical and Economic Review - has found that three therapies for the ultra-rare and potentially fatal disorder hereditary angioedema (HAE) are not cost-effective.

In a “Final Evidence” report, the ICER compares the clinical and economic value of Shire’s (LSE: SHP) Takhzyro (lanadelumab) and Cinryze (C1 esterase inhibitor), and CSL Behring’s Haegarda (C1 esterase inhibitor).

The Boston, USA-based group says that all three therapies “at current pricing, exceed commonly cited thresholds for cost-effectiveness.”